glp-1 receptor agonists and cardiovascular outcome trials an update Results of outcomes comparing GLP-1 receptor agonists (GLP-1RAs): cardiovascular
Description
Sandsdal et al
How does Ozempic work as a GLP-1 medication for weight loss
Liraglutide was shown to prevent synapse loss and deterioration of synapse plasticity in the hippocampus of APP/PS1 mice, while enhance synaptic plasticity in the control mice (158, 175)
30249-9/asset/ae163e52-907c-4c99-987f-36b369e8996a/main.assets/gr3.gif)
HbA1c reduction 4.1.1
In a 48-week, placebo-controlled phase-2 trial (338 participants) reported by Lilly, the highest dose achieved a mean weight reduction of 24.2% (about 57.8 lb) at the end of treatment
Buckley and colleagues conducted a study where participants received a dose of oral semaglutide in either a fasting or fed state
